[go: up one dir, main page]

MX2019006920A - Derivados de la espiropiperidina. - Google Patents

Derivados de la espiropiperidina.

Info

Publication number
MX2019006920A
MX2019006920A MX2019006920A MX2019006920A MX2019006920A MX 2019006920 A MX2019006920 A MX 2019006920A MX 2019006920 A MX2019006920 A MX 2019006920A MX 2019006920 A MX2019006920 A MX 2019006920A MX 2019006920 A MX2019006920 A MX 2019006920A
Authority
MX
Mexico
Prior art keywords
disclosed
compounds
spiropiperidine
fatty acid
methods
Prior art date
Application number
MX2019006920A
Other languages
English (en)
Other versions
MX392586B (es
Inventor
Mcwherter Melody
L Hudkins Robert
B Whitman David
A Zificsak Craig
L Zulli Allison
Original Assignee
89Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 89Bio Ltd filed Critical 89Bio Ltd
Publication of MX2019006920A publication Critical patent/MX2019006920A/es
Publication of MX392586B publication Critical patent/MX392586B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen compuestos de espiropiperidina de acuerdo con la Fórmula l que han demostrado actividad como inhibidores de ácido graso sintasa. En la presente también se describen composiciones farmacéuticas que contienen los compuestos de espiropiperidina descritos, y métodos para tratar enfermedades mediadas por ácido graso sintasas, mediante la administración de uno o más de los compuestos o formulaciones farmacéuticas descritas en la presente. En la presente también se describen métodos para sintetizar los compuestos descritos, incluyendo los compuestos de espiropiperidina descritos y los productos intermedios sintéticos que son útiles en tales síntesis. (Ver fórmula).
MX2019006920A 2016-12-14 2017-12-14 Derivados de la espiropiperidina. MX392586B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662434167P 2016-12-14 2016-12-14
PCT/US2017/066422 WO2018112204A1 (en) 2016-12-14 2017-12-14 Spiropiperidine derivatives

Publications (2)

Publication Number Publication Date
MX2019006920A true MX2019006920A (es) 2019-11-28
MX392586B MX392586B (es) 2025-03-24

Family

ID=62559235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006920A MX392586B (es) 2016-12-14 2017-12-14 Derivados de la espiropiperidina.

Country Status (7)

Country Link
US (3) US11046707B2 (es)
EP (1) EP3554637A4 (es)
JP (2) JP7162591B2 (es)
CA (1) CA3046805A1 (es)
IL (1) IL267145B (es)
MX (1) MX392586B (es)
WO (1) WO2018112204A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017174980A2 (en) 2016-04-08 2017-10-12 John Phillip Chevalier Latching systems for latching movable panels
US11046707B2 (en) * 2016-12-14 2021-06-29 89Bio Ltd Spiropiperidine derivatives
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113793910B (zh) * 2021-10-22 2024-11-26 浙江华显光电科技有限公司 有机光电器件及包含其的显示或照明装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155108A1 (en) 1993-02-12 1994-08-18 John J. Baldwin Nitrogen-containing spirocycles
EP1910375B1 (en) 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
WO2007054580A1 (en) * 2005-11-14 2007-05-18 Solvay Pharmaceuticals Gmbh N-sulfamoyl-n’-benzopyranpiperidines as inhbitors of carbonic anhydrases
TW200804393A (en) * 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
US8138197B2 (en) 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2250176B1 (en) * 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
AU2009266730B2 (en) * 2008-07-04 2013-07-18 Msd K.K. Novel spirochromanone carboxylic acids
JPWO2012161119A1 (ja) * 2011-05-20 2014-07-31 興和株式会社 新規なスピロピペリジン誘導体及びこれを含有する医薬
CN103304571B (zh) * 2012-03-06 2018-02-16 凯惠科技发展(上海)有限公司 螺环化合物、其制备方法、中间体、药物组合物和应用
US20190181928A1 (en) 2016-08-10 2019-06-13 Idac Holdings, Inc. Spatial modulation for next generation wireless systems
US11046707B2 (en) * 2016-12-14 2021-06-29 89Bio Ltd Spiropiperidine derivatives

Also Published As

Publication number Publication date
US20200031840A1 (en) 2020-01-30
US12448392B2 (en) 2025-10-21
JP2022166192A (ja) 2022-11-01
US11878982B2 (en) 2024-01-23
US20240166661A1 (en) 2024-05-23
JP2020511412A (ja) 2020-04-16
WO2018112204A1 (en) 2018-06-21
CA3046805A1 (en) 2018-06-21
IL267145A (en) 2019-08-29
US11046707B2 (en) 2021-06-29
IL267145B (en) 2022-01-01
EP3554637A1 (en) 2019-10-23
JP7162591B2 (ja) 2022-10-28
EP3554637A4 (en) 2020-05-20
US20210284651A1 (en) 2021-09-16
MX392586B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
CO2018000344A2 (es) Derivados de piperidina 1,4-sustituidos
MX2019006920A (es) Derivados de la espiropiperidina.
MX2017016370A (es) Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CO2018004124A2 (es) Compuestos heterocíclicos
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
MX2019001011A (es) Compuestos farmaceuticos.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP18014798A (es) Inhibidores de ezh2
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
CR20180560A (es) Ésteres de oxaboral y sus usos
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
IN2014MN02393A (es)
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2017009452A (es) Agentes de imagenologia para tomografia de emision de positrones (pet).